Company Interview / Cyclopharm's Technegas breathing life into US expansion

James McBrayer from Cyclopharm (ASX:CYC) states that their lung ventilation agent, Technegas, is expanding its use in respiratory care. Technegas is widely known for diagnosing pulmonary embolisms and it's gaining traction in preoperative lung transplant planning in the US. This innovation potentially replaces older methods like xenon imaging.

James highlights Technegas rapid administration benefits and advancements in imaging techniques. The technology is applied worldwide, enhancing the diagnosis and management of conditions such as COPD, asthma, and lung transplants. Recent US Veterans Health Authority sales indicate growing domestic demand.

James envisions significant growth in the US market, already being Cyclopharm's (ASX:CYC) largest. The French clinical trial underscores Technegas pivotal role, especially compared to CT scans. Although heavy investments are made in the US, Cyclopharm aims for profitability by next year, ensuring a positive cash flow.